Definium Therapeutics (MMQ0) Financial Statements
Definium Therapeutics Financial Overview
Definium Therapeutics's market cap is currently $4.37B. The company's EPS TTM is $-3.44; its P/E ratio is -10.56; Definium Therapeutics is estimated to report earnings on November 9, 2026, and the estimated EPS forecast is $-0.50. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ -527.00K | $ -3.16M | $ 0.00 | $ 0.00 |
| Operating Income | $ -166.31M | $ -103.92M | $ -93.87M | $ -66.33M | $ -93.85M |
| EBITDA | $ -178.31M | $ -105.87M | $ -92.57M | $ -52.12M | $ -91.22M |
| Net Income | $ -183.79M | $ -108.68M | $ -95.73M | $ -56.80M | $ -93.04M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 411.59M | $ 273.74M | $ 99.70M | $ 142.14M | $ 133.54M |
| Total Assets | $ 440.10M | $ 302.15M | $ 124.54M | $ 169.99M | $ 164.00M |
| Total Debt | $ 0.00 | $ 21.85M | $ 14.13M | $ 72.00K | $ 0.00 |
| Net Debt | $ -257.84M | $ -251.89M | $ -85.58M | $ -142.07M | $ -133.54M |
| Total Liabilities | $ 107.77M | $ 60.70M | $ 46.41M | $ 19.08M | $ 12.34M |
| Stockholders' Equity | $ 332.33M | $ 241.45M | $ 78.13M | $ 150.92M | $ 151.66M |
| Cash Flow | |||||
| Free Cash Flow | $ -131.56M | $ -79.13M | $ -64.36M | $ -50.14M | $ -45.82M |
| Operating Cash Flow | $ -131.56M | $ -79.13M | $ -64.36M | $ -50.14M | $ -45.82M |
| Investing Cash Flow | $ -151.61M | $ 0.00 | $ 0.00 | $ 0.00 | $ -297.00K |
| Financing Cash Flow | $ 267.27M | $ 253.20M | $ 21.85M | $ 59.05M | $ 98.82M |
Currency in USD
